Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | -- |
Average volume | -- |
---|---|
Shares outstanding | 291.53m |
Free float | 271.55m |
P/E (TTM) | -- |
Market cap | 2.02bn USD |
EPS (TTM) | -1.63 USD |
--
More ▼
Announcements
- Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma
- Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability
- CORRECTION - Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results
- Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities
- Recursion updates L(earnings) call on August 8th to 8:30 am ET / 6:30 am MT
- Recursion to Report Second Quarter 2024 Business Updates and Financial Results on August 8th
- Recursion Announces Pricing of $200 Million Public Offering of Class A Common Stock
- Recursion Announces Proposed Offering of Class A Common Stock
- Recursion Gives Guidance on Seven Clinical Readouts within ~18 Months and Partnership Updates at Their Download Day
- Recursion to Participate in Upcoming Investor Conferences
More ▼